Daniela Scattolin

Daniela Scattolin

Auto-generated profile, based on publicly available information

Daniela Scattolin

Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Department of Respiratory Medicine, Erasmus MC Cancer Institute, University Medical Centre, Rotterdam, the Netherlands

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2025 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Open access
DSDaniela Scattolin
Daniela Scattolin
FHFrank W.J. Heijboer
Frank W.J. Heijboer
JDJules L. Derks
Jules L. Derks
JTJan H von der Thüsen
Jan H von der Thüsen
DDDaphne Dumoulin
Daphne Dumoulin
ADAnne-Marie C. Dingemans
Anne-Marie C. Dingemans
Schlafen 11 (SLFN11) is a gene encoding for a protein involved in the irreversible arrest of cell replication under DNA-damaging stress. SLFN11 is expressed differently across various cancers. When overexpressed, SLFN11 inhibits tumor replication and growth by early recruitment to stressed replication forks, making tumors more sensitive to a range of anti-cancer treatments, including topoisomerase I-II inhibitors, DNA alkylating agents, platinum salts, anti-metabolites, anti-tumor antibiotics, poly ADP-ribose polymerase (PARP) inhibitors and immunotherapies. SLFN11 expression can be silenced in cancer cells through different epigenetic mechanisms, resulting in SLFN11 downregulation and resistance to anti-cancer treatments. In this context, SLFN11 is increasingly being recognized as a promising biomarker for predicting cancer treatment responses. Its expression levels can inform clinical decisions, helping to identify patients most likely to benefit from therapies that exploit replication stress and to select new drug combinations that specifically aim to overcome SLFN11 deficiency.

25 September 2025 in Lung Cancer
Verified
Journal Article
Open access
Maria Lucia RealeMaria Lucia Reale
Maria Lucia Reale
DSDaniela Scattolin
Daniela Scattolin
AVAntonio Vitale
Antonio Vitale
FPFrancesco Passiglia
Francesco Passiglia
SGSalvatore Grisanti
Salvatore Grisanti
GPGiulia Pasello
Giulia Pasello
Treatment of advanced ALK + NSCLC has improved with increasingly effective ALK tyrosine-kinase inhibitors (TKIs). We report real-world treatment patterns and outcomes from the Italian ATLAS registry. Clinical-pathological and treatment data were retrospectively and prospectively collected from 37 Italian centers. 463 ALK + advanced NSCLC patients treated from 2019 to 2024 were included. 431 (93 %) patients received 1st line (1L) ALK TKIs, mostly alectinib (82.5 %). 1L treatment choice, reported in 142 cases, was driven by drug access as first (31 %) or subsequent lines (40.1 %) and by safety (21.8 %). Among 382 patients receiving 1L alectinib overall survival (OS) rate was 88.7 % and 73.3 % at 24 and 60 months, respectively. Median progression-free survival (mPFS) was 43.1 months (95 %CI: 29.5-57.0). Brain was a new site of progression in 11 (3.6 %) patients. Intracranial PFS rate was 73.1 % and 59.1 % at 24 and 36 months with a 64.7 % intracranial response rate. Grade ≥ 3 adverse events occurred in 41 (10.7 %) patients, mainly hepatic toxicity (13, 3.4 %) and asthenia (5, 1.3 %). At progression tissue and/or liquid biopsy were performed in 28 (23.5 %) and 20 (16.8 %) cases, respectively. Out of 80 patients receiving 2nd line therapy after alectinib, 67 (83.8 %) received lorlatinib achieving mPFS 7.5 (95 % CI: 6.2-8.8) and mOS 26.4 months (95 % CI: 19.1-33.7). 17 (15.5 %) patients died without second line therapy. Real-world data confirm the effectiveness and safety of alectinib, used as preferred upfront ALK-TKI. The recent 1L lorlatinib approval might change this scenario. Tissue/liquid biopsy at disease progression are underperformed in clinical practice.

3 July 2025 in European Journal of Cancer
Verified
Journal Article
Open access
DSDaniela Scattolin
Daniela Scattolin
ADAnne-Marie C Dingemans
Anne-Marie C Dingemans
AMAlessandro Dal Maso
Alessandro Dal Maso
VGValentina Guarneri
Valentina Guarneri
JAJoachim G.J.V. Aerts
Joachim G.J.V. Aerts
DDDaphne Dumoulin
Daphne Dumoulin
Lurbinectedin has recently emerged in the treatment landscape of extensive stage (ES) small cell lung cancer (SCLC). Here we report the outcomes and safety of lurbinectedin within a named patient program in a multicentric, international cohort. Clinical data of all patients with ES-SCLC treated with lurbinectedin at the Erasmus Medical Center (EMC, Rotterdam-The Netherlands) and the Veneto Institute of Oncology (IOV, Padua-Italy) were collected. A total of 238 patients receiving lurbinectedin as second- (37 %), third- (45 %) or further-line (18 %) were included. Median number of cycles was 3 (1-22). The objective response rate was 23.1 %, the disease control rate 45.5 %. The median progression free survival (PFS) 2.2 months (95 %CI 1.6-2.8) and the median overall survival (OS) 5.4 months (95 %CI 4.5-6.3). Patients with a chemotherapy-free interval (CFI) ≥ 90 days showed a longer PFS (3.1 vs 1.8 months, HR 0.46, 0.30-0.71, p < 0.001) and OS (6.8 vs 4.5 months, HR 0.56, 0.37-0.85, p = 0.006). Patients with ECOG performance status (PS) ≥ 2 at lurbinectedin start, brain or liver metastasis showed a worse outcome. Adverse events were recorded in 218 (92 %) patients, with 29 % grade 3-4 events. Considering its safety profile and modest but consistent effectiveness, lurbinectedin represents a therapeutic option as compassionate use in patients with ES-SCLC, especially in those with a long CFI. Poor PS, CFI < 90 days, brain or liver metastases may affect the OS.

22 November 2025 in Lung Cancer
Verified
Journal Article
Open access
ESEvgeniya Sharova
Evgeniya Sharova
PBPaola Del Bianco
Paola Del Bianco
LULoredana Urso
Loredana Urso
MSMicol Silic-Benussi
Micol Silic-Benussi
DSDaniela Scattolin
Daniela Scattolin
Vincenzo CiminaleVincenzo Ciminale
Vincenzo Ciminale
Pleural mesothelioma (PM) is an aggressive neoplasm associated with asbestos exposure. Clinical management of PM poses major challenges due to the lack of reliable markers for early diagnosis and prognostic stratification. Here we evaluated circulating microRNAs (miRNAs) as minimally invasive biomarkers for PM detection and risk assessment. Plasma samples were collected from 32 asbestos-exposed (AsbEX) individuals and 56 PM patients, including epithelioid (N = 45) and non-epithelioid (N = 11) subtypes. An initial discovery cohort (9 AsbEX and 9 PM) was screened for 92 miRNAs using quantitative RT-PCR. Candidate miRNAs were validated in the full cohort. Ratios calculated from the plasma levels of miR-24-3p, miR-146a-5p, miR-191-5p, miR-200a-3p, miR-222-3p, miR-223-3p, and miR-1260a robustly differentiated PM patients from asbestos-exposed controls with high accuracy and sensitivity. Furthermore, ratios of circulating miR-146a-5p, miR-200a-3p, miR-222-3p and miR-191-5p enabled stratification of epithelioid PM in high- and low-risk prognostic groups. Circulating miRNA signatures represent promising non-invasive biomarkers for early PM detection and prognostic stratification, particularly in epithelioid cases. Incorporation of these biomarkers into clinical workflows could pave the way for more personalized treatment strategies and optimize patient selection for surgery.

10 April 2026 in Lung Cancer
Verified
Journal Article
Open access
GPGiulia Pasello
Giulia Pasello
GPGiulia Pigato
Giulia Pigato
CMCristiana Mulargiu
Cristiana Mulargiu
FFFederica Ferrarini Ferrarini
Federica Ferrarini Ferrarini
FPFederica Pezzuto
Federica Pezzuto
SIStefano Indraccolo
Stefano Indraccolo
Lung neuroendocrine tumors (LNETs) span well-differentiated typical/atypical carcinoids (TC/AC) to poorly differentiated large-cell neuroendocrine carcinoma (LCNEC). Robust biomarkers for grading and prognostication are lacking. We hypothesized that differential metabolic pathways activation, reflected by protein expression, holds prognostic relevance. We conducted a monocentric translational study on resected LNETs to characterize biomarkers involved in glycolysis, fatty acid, and amino acid pathways across different grades of LNETs. Secondary endpoints included assessing clinical outcomes and correlating biomarker expression with patient prognosis. Digital FFPE sections underwent standardized immunohistochemistry (IHC) and quantitative image analysis. Biomarkers included glycolysis (MCT1, MCT4, CD147), amino-acid metabolism (SLC1A5, SLC7A5, GLS), and fatty-acid synthesis (FAS, ACC). Expression was summarized by H-score and dichotomized. Associations with clinicopathologic variables, recurrence-free survival (RFS), and overall survival (OS) were tested using median and maximally selected rank statistics. Overall, 49 LNETs were included: 11 TC, 19 AC; 19 LCNEC. LCNEC showed marked upregulation of glycolytic and amino-acid transport markers versus TC/AC. Fatty-acid markers were generally low across subtypes. High MCT1 and SLC7A5 predicted shorter OS; MCT1 and CD147 predicted shorter RFS. In multivariable analysis, MCT1 remained independently associated with RFS. Notably, a subset of ACs with elevated glycolysis/amino-acid markers showed LCNEC-like outcomes, independent of Ki-67. GLS peaked in AC, suggesting divergent glutamine utilization along the spectrum. Quantitative digital pathology reveals distinct metabolic signatures in LNETs. MCT1 and SLC7A5 emerge as prognostic biomarkers, with MCT1 independently predicting RFS. Integrating metabolic immunophenotyping with histopathology refines risk stratification-especially for AC-and highlights potentially actionable metabolic axes for future therapeutic interventions in LNETs.